ClinicalTrials.gg
CompletedNCT03218995Updated Dec 9, 2021Results posted

Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping

A Phase 2 interventional study of Eteplirsen in Duchenne Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Completed at 4 sites in 4 countries. Open to male participants aged 6 Months to 48 Months. Per ClinicalTrials.gov, last updated 2021-12-09.

Sponsored by Sarepta Therapeutics, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
6 Months to 48 Months
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne — none open to participants now, none under way, none of them phase 3. eteplirsen · Muscular Dystrophy, Duchenne.

Enrollment
6th of 11
15 · median 15
Started
2017
the only one that year
Phase 2
7 of 11
none open now
Registered
8th of 11
by date
Lead sponsor
9 of 11
Sarepta Therapeutics, Inc.

Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, this one is the 6th largest by enrollment, is the only one that started in 2017, is one of 7 in phase 2, and was the 8th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

None of the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne is open now. The open studies under Muscular Dystrophy, Duchenne, anywhere →

About eteplirsen

eteplirsen: first FDA approval 2016 (EXONDYS 51). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 6 Months to 48 Months · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne as a file.
02

Study summary

This is a multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, and PK of once-weekly IV infusions of eteplirsen in approximately 12 male participants, ages 6 months to 48 months (inclusive), who have genotypically confirmed DMD with a deletion mutation amenable to exon 51 skipping.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • DMD
  • Duchenne
  • Eteplirsen
  • dystrophy
  • dystrophin
  • exon 51
04

Who can participate

Ages eligible
6 Months to 48 Months
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male between 6 months to 48 months of age (inclusive)
  • Diagnosis of DMD with a deletion mutation amenable to exon 51 skipping
  • Parent(s) or legal guardian(s) who is willing to provide written

Exclusion criteria

Exclusion Criteria:

  • Received treatment that might have an effect on muscle strength or function within 12 weeks prior to dosing
  • Received previous or current treatment with any experimental treatment
  • illness other than DMD
  • Clinically significant laboratory abnormality
  • Any other condition that could interfere with the participation in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Eteplirsen

    Eteplirsen will be administered once every 7 days by intravenous (IV) infusion starting on Day 1 for up to 96 weeks. The starting dose will be 2 milligrams/kilogram (mg/kg) eteplirsen, with escalation to 4, 10, 20, and 30 mg/kg for 10 weeks, and then participants will continue to receive eteplirsen at 30 mg/kg for the duration of the study.

    Drug: Eteplirsen

Interventions

  • Infusion for intravenous use.

    Also known as: AVI-4658, EXONDYS 51®

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and TEAEs Leading to Discontinuation From Study Drug

    TEAEs were defined as adverse events (AEs) with an onset following administration of the first dose of study drug. An AE was any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with the study drug. Abnormalities presented at Baseline were considered AEs if they reoccurred after resolution or worsen during the AE collection period. An SAE was defined as any AE that, in the view of either the Investigator or Sponsor, resulted in any of the following outcomes as fatal, life-threatening, required hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or an important medical event. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in the 'Adverse Events' Section.

    Time frame: Baseline up to Week 100

  2. Number of Participants With at Least 1 Potentially Clinically Significant Clinical Safety Laboratory Abnormality

    Clinical laboratory parameters that were evaluated included * Any Grade ≥2 (moderate) or serious event without an alternative etiology that the Investigator deemed was related to study drug * Two consecutive drug-related serum creatinine levels ≥2\*upper limit of normal (ULN) without an alternative etiology * Creatine kinase (CK) levels \>50,000 units/liter (U/L) * A confirmed, unexplained, increase in gamma glutamyl transferase (GGT) \>3\*ULN and either an increase in bilirubin \>2\*ULN or nascent prothrombin time \>2\*ULN concurrently, without an alternative etiology

    Time frame: Baseline up to Week 100

  3. Number of Participants With at Least 1 Markedly Abnormal Vital Sign

    The vital sign parameters that were evaluated included blood pressure, heart rate, respiration, and temperature. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in the 'Adverse Events' Section.

    Time frame: Baseline up to Week 100

  4. Abnormal Changes From Baseline or Worsening of Physical Examination Findings

    Data not collected during the study for this Outcome Measure. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in the 'Adverse Events' Section.

    Time frame: Baseline up to Week 100

  5. Number of Participants With at Least 1 Markedly Abnormal Electrocardiogram (ECG) and Echocardiogram (ECHO)

    The ECG was manually reviewed and interpreted by medically qualified personnel using a central vendor according to pre-specified criteria. The Investigator determined if the findings in the centrally read ECG report were clinically significant. Clinical significance was defined as any variation in ECG findings that had medical relevance resulting in an alteration in medical care. The ECHO was reviewed and interpreted by medically qualified personnel using a central vendor according to pre-specified criteria. The Investigator determined if the findings in the ECHO report were clinically significant. Clinical significance was defined as any variation in ECHO findings that had medical relevance resulting in an alteration in medical care. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in the 'Adverse Events' Section.

    Time frame: Weeks 8, 12, 24, 36, 48, 60, 72, 84, 96

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) of Eteplirsen

    Time frame: Pre-infusion, immediately prior to end of infusion, and approximately 1-3 hours and 6-8 hours after completion of infusion during Weeks 2 (2 mg/kg dose level), 6 (10 mg/kg dose level), 8 (20 mg/kg dose level), and 10 and 24 (30 mg/kg dose level)

  2. Time to Reach Maximum Plasma Concentration (Tmax) of Eteplirsen

    Time frame: Pre-infusion, immediately prior to end of infusion, and approximately 1-3 hours and 6-8 hours after completion of infusion during Weeks 2 (2 mg/kg dose level), 6 (10 mg/kg dose level), 8 (20 mg/kg dose level), and 10 and 24 (30 mg/kg dose level)

  3. Area Under Concentration-Time Curve From Time 0 to the Last Quantifiable Concentration (AUClast) of Eteplirsen in Plasma

    Time frame: Pre-infusion, immediately prior to end of infusion, and approximately 1-3 hours and 6-8 hours after completion of infusion during Weeks 2 (2 mg/kg dose level), 6 (10 mg/kg dose level), 8 (20 mg/kg dose level), and 10 and 24 (30 mg/kg dose level)

  4. Amount of Drug Eliminated in Urine

    Amount of unchanged drug excreted in urine from time 0 to 4 hours after completion of dosing is reported.

    Time frame: Pre-infusion, immediately prior to end of infusion, and approximately 1-3 hours and 6-8 hours after completion of infusion during Weeks 2 (2 mg/kg dose level), 6 (10 mg/kg dose level), 8 (20 mg/kg dose level), and 10 and 24 (30 mg/kg dose level)

07

Results

Posted Dec 9, 2021

Participant flow

Participant flow — Overall Study
MilestoneEteplirsen
Started15
Received at least 1 dose of study drug15
Completed15
Not completed0

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and TEAEs Leading to Discontinuation From Study Drug

TEAEs were defined as adverse events (AEs) with an onset following administration of the first dose of study drug. An AE was any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with the study drug. Abnormalities presented at Baseline were considered AEs if they reoccurred after resolution or worsen during the AE collection period. An SAE was defined as any AE that, in the view of either the Investigator or Sponsor, resulted in any of the following outcomes as fatal, life-threatening, required hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or an important medical event. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in the 'Adverse Events' Section.

Time frame:
Baseline up to Week 100
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and TEAEs Leading to Discontinuation From Study Drug
ParticipantsCohort 1: Age 24 to 48 MonthsCohort 2: Age 6 to <24 Months
TEAE96
SAE01
AE leading to discontinuation from study drug00
PrimaryNumber of Participants With at Least 1 Potentially Clinically Significant Clinical Safety Laboratory Abnormality

Clinical laboratory parameters that were evaluated included * Any Grade ≥2 (moderate) or serious event without an alternative etiology that the Investigator deemed was related to study drug * Two consecutive drug-related serum creatinine levels ≥2\*upper limit of normal (ULN) without an alternative etiology * Creatine kinase (CK) levels \>50,000 units/liter (U/L) * A confirmed, unexplained, increase in gamma glutamyl transferase (GGT) \>3\*ULN and either an increase in bilirubin \>2\*ULN or nascent prothrombin time \>2\*ULN concurrently, without an alternative etiology

Time frame:
Baseline up to Week 100
Reported as:
Count of participants · Participants
Number of Participants With at Least 1 Potentially Clinically Significant Clinical Safety Laboratory Abnormality
ParticipantsCohort 1: Age 24 to 48 MonthsCohort 2: Age 6 to <24 Months
Number of Participants With at Least 1 Potentially Clinically Significant Clinical Safety Laboratory Abnormality96
PrimaryNumber of Participants With at Least 1 Markedly Abnormal Vital Sign

The vital sign parameters that were evaluated included blood pressure, heart rate, respiration, and temperature. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in the 'Adverse Events' Section.

Time frame:
Baseline up to Week 100
Reported as:
Count of participants · Participants
Number of Participants With at Least 1 Markedly Abnormal Vital Sign
ParticipantsCohort 1: Age 24 to 48 MonthsCohort 2: Age 6 to <24 Months
Number of Participants With at Least 1 Markedly Abnormal Vital Sign96
PrimaryAbnormal Changes From Baseline or Worsening of Physical Examination Findings

Data not collected during the study for this Outcome Measure. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in the 'Adverse Events' Section.

Time frame:
Baseline up to Week 100

No measurements were reported for this outcome.

PrimaryNumber of Participants With at Least 1 Markedly Abnormal Electrocardiogram (ECG) and Echocardiogram (ECHO)

The ECG was manually reviewed and interpreted by medically qualified personnel using a central vendor according to pre-specified criteria. The Investigator determined if the findings in the centrally read ECG report were clinically significant. Clinical significance was defined as any variation in ECG findings that had medical relevance resulting in an alteration in medical care. The ECHO was reviewed and interpreted by medically qualified personnel using a central vendor according to pre-specified criteria. The Investigator determined if the findings in the ECHO report were clinically significant. Clinical significance was defined as any variation in ECHO findings that had medical relevance resulting in an alteration in medical care. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in the 'Adverse Events' Section.

Time frame:
Weeks 8, 12, 24, 36, 48, 60, 72, 84, 96
Reported as:
Count of participants · Participants
Number of Participants With at Least 1 Markedly Abnormal Electrocardiogram (ECG) and Echocardiogram (ECHO)
ParticipantsCohort 1: Age 24 to 48 MonthsCohort 2: Age 6 to <24 Months
Number of Participants With at Least 1 Markedly Abnormal Electrocardiogram (ECG) and Echocardiogram (ECHO)45
SecondaryMaximum Plasma Concentration (Cmax) of Eteplirsen
Time frame:
Pre-infusion, immediately prior to end of infusion, and approximately 1-3 hours and 6-8 hours after completion of infusion during Weeks 2 (2 mg/kg dose level), 6 (10 mg/kg dose level), 8 (20 mg/kg dose level), and 10 and 24 (30 mg/kg dose level)
Reported as:
Geometric mean · microgram/milliliter (μg/mL)
Maximum Plasma Concentration (Cmax) of Eteplirsen
microgram/milliliter (μg/mL)Cohort 1: Age 24 to 48 MonthsCohort 2: Age 6 to <24 Months
Week 2 (2 mg/kg)9.67 ± 75.94.22 ± 120
Week 6 (10 mg/kg)46.5 ± 72.317.2 ± 192
Week 8 (20 mg/kg)63.3 ± 12385.0 ± 67.6
Week 10 (30 mg/kg)93.7 ± 55.563.8 ± 124
Week 24 (30 mg/kg)78.2 ± 92.259.7 ± 82.7
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of Eteplirsen
Time frame:
Pre-infusion, immediately prior to end of infusion, and approximately 1-3 hours and 6-8 hours after completion of infusion during Weeks 2 (2 mg/kg dose level), 6 (10 mg/kg dose level), 8 (20 mg/kg dose level), and 10 and 24 (30 mg/kg dose level)
Reported as:
Median · hours (hr)
Time to Reach Maximum Plasma Concentration (Tmax) of Eteplirsen
hours (hr)Cohort 1: Age 24 to 48 MonthsCohort 2: Age 6 to <24 Months
2 mg/kg (Week 2)0.58 (0.17 to 2.67)0.58 (0.42 to 0.67)
10 mg/kg (Week 6)0.58 (0.47 to 4.25)0.72 (0.58 to 3.32)
20 mg/kg (Week 8)0.78 (0.50 to 2.75)0.73 (0.53 to 1.17)
30 mg/kg (Week 10)0.58 (0.50 to 1.48)0.92 (0.50 to 2.75)
30 mg/kg (Week 24)0.63 (0.42 to 6.83)0.72 (0.58 to 1.83)
SecondaryArea Under Concentration-Time Curve From Time 0 to the Last Quantifiable Concentration (AUClast) of Eteplirsen in Plasma
Time frame:
Pre-infusion, immediately prior to end of infusion, and approximately 1-3 hours and 6-8 hours after completion of infusion during Weeks 2 (2 mg/kg dose level), 6 (10 mg/kg dose level), 8 (20 mg/kg dose level), and 10 and 24 (30 mg/kg dose level)
Reported as:
Geometric mean · μg*hr/mL
Area Under Concentration-Time Curve From Time 0 to the Last Quantifiable Concentration (AUClast) of Eteplirsen in Plasma
μg*hr/mLCohort 1: Age 24 to 48 MonthsCohort 2: Age 6 to <24 Months
2 mg/kg (Week 2)13.8 ± 1186.13 ± 73.1
10 mg/kg (Week 6)56.1 ± 57.227.8 ± 113
20 mg/kg (Week 8)92.1 ± 94.781.4 ± 89.6
30 mg/kg (Week 10)119 ± 30.885.0 ± 114
30 mg/kg (Week 24)100 ± 42.589.6 ± 43.8
SecondaryAmount of Drug Eliminated in Urine

Amount of unchanged drug excreted in urine from time 0 to 4 hours after completion of dosing is reported.

Time frame:
Pre-infusion, immediately prior to end of infusion, and approximately 1-3 hours and 6-8 hours after completion of infusion during Weeks 2 (2 mg/kg dose level), 6 (10 mg/kg dose level), 8 (20 mg/kg dose level), and 10 and 24 (30 mg/kg dose level)
Reported as:
Mean · μg
Amount of Drug Eliminated in Urine
μgCohort 1: Age 24 to 48 MonthsCohort 2: Age 6 to <24 Months
2 mg/kg dose (Week 2)7720 ± 90601430 ± 1390
10 mg/kg (Week 6)56000 ± 7330028700 ± 24100
20 mg/kg (Week 8)102000 ± 10800065600 ± 47900
30 mg/kg (Week 10)263000 ± 20900094700 ± 68500
30 mg/kg (Week 24)239000 ± 140000147000 ± 132000

Adverse events

Collected over Baseline up to Week 100. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Age 24 to 48 Months0/9 (0%)0/9 (0%)9/9 (100%)
Cohort 2: Age 6 to <24 Months0/6 (0%)1/6 (16.7%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventCohort 1: Age 24 to 48 MonthsCohort 2: Age 6 to <24 Months
BronchiolitisInfections and infestations0/91/6
Most frequent other events
Showing 10 of 107
Most frequent other events
EventCohort 1: Age 24 to 48 MonthsCohort 2: Age 6 to <24 Months
PyrexiaGeneral disorders7/96/6
VomitingGastrointestinal disorders8/94/6
NasopharyngitisInfections and infestations7/95/6
CoughRespiratory, thoracic and mediastinal disorders7/95/6
RhinitisInfections and infestations4/94/6
DiarrhoeaGastrointestinal disorders5/93/6
FallInjury, poisoning and procedural complications5/92/6
Head injuryInjury, poisoning and procedural complications5/92/6
Ear infectionInfections and infestations3/93/6
GastroenteritisInfections and infestations3/93/6

Baseline characteristics

The Safety Set included all participants who were enrolled and received at least 1 dose of eteplirsen during the study.

Age, Continuous
Age, Continuous(months)Overall Study
Mean28.5 ± 12.94
Age, Customized
Age, Customized(Participants)Overall Study
In utero0
Preterm newborn infants (gestational age < 37 wks)0
Newborns (0-27 days)0
Infants and toddlers (28 days-23 months)6
Children (2-11 years)9
Adolescents (12-17 years)0
Adults (18-64 years)0
From 65-84 years0
85 years and over0
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female0
Male15
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall Study
Hispanic or Latino0
Not Hispanic or Latino7
Unknown or Not Reported8
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall Study
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White9
More than one race1
Unknown or Not Reported5
08

Study locations

4 sites
  • Universitair ziekenhuis Gent
    Gent, 9000, Belgium
  • Armand-Trousseau Hospital
    Paris, 75012, France
  • Site Fondazione Policlinico Universitario Agostino Gemelli
    Roma, Italy
  • UCL Great Ormond Street Institute of Child Health
    London, WC1N 1EH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Mar 2021, 42 months.

Results were first posted in Dec 2021, 8 months after primary completion.

Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's 42 months is above that.

Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2017
First posted
Jul 17, 2017
StartActual
Aug 16, 2017
Primary completionActual
Mar 10, 2021
CompletionActual
Mar 10, 2021
Results first posted
Dec 9, 2021
Last update
Dec 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03218995
Responsible party
Sponsor
First posted
Jul 17, 2017
Start date
Aug 16, 2017
Primary completion
Mar 10, 2021
Completion
Mar 10, 2021
Results posted
Dec 9, 2021
Last update
Dec 9, 2021

Study contacts

Medical Director
study chair · Sarepta Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eteplirsen

Start the discussion